Capricor Therapeutics Stock Alpha and Beta Analysis
| CAPR Stock | USD 8.18 1.44 21.36% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Capricor Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Capricor Therapeutics over a specified time horizon. Remember, high Capricor Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Capricor Therapeutics' market risk premium analysis include:
Beta 4.88 | Alpha (1.28) | Risk 10.45 | Sharpe Ratio (0) | Expected Return (0.02) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Capricor Therapeutics Backtesting, Capricor Therapeutics Valuation, Capricor Therapeutics Correlation, Capricor Therapeutics Hype Analysis, Capricor Therapeutics Volatility, Capricor Therapeutics History and analyze Capricor Therapeutics Performance. Capricor Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Capricor Therapeutics market risk premium is the additional return an investor will receive from holding Capricor Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Capricor Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Capricor Therapeutics' performance over market.| α | -1.28 | β | 4.88 |
Capricor Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Capricor Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Capricor Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Capricor Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Capricor Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Capricor Therapeutics shares will generate the highest return on investment. By understating and applying Capricor Therapeutics stock market price indicators, traders can identify Capricor Therapeutics position entry and exit signals to maximize returns.
Capricor Therapeutics Return and Market Media
The median price of Capricor Therapeutics for the period between Fri, May 2, 2025 and Thu, Jul 31, 2025 is 10.18 with a coefficient of variation of 23.69. The daily time series for the period is distributed with a sample standard deviation of 2.35, arithmetic mean of 9.94, and mean deviation of 1.96. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 750 shares by Dunbar George W Jr of Capricor Therapeutics at 1. subject to Rule 16b-3 | 05/02/2025 |
2 | Capricor Therapeutics initiated with bullish view at B. Riley, heres why CAPR | 06/26/2025 |
3 | Capricor Therapeutics Maintains Buy Rating Amid FDA Feedback CAPR Stock News | 07/11/2025 |
4 | Bragar Eagel Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm | 07/16/2025 |
5 | DEADLINE ALERT Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor ... | 07/18/2025 |
6 | Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending Contact The Gross ... | 07/21/2025 |
7 | ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. ... | 07/22/2025 |
8 | INVESTOR ALERT Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors ofCapricor Therapeutics, Inc. - CAPR | 07/23/2025 |
9 | CAPR INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Capricor ... | 07/24/2025 |
10 | CAPR Class Action Alert Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Capricor Therapeutics, Inc. Securities Class Action | 07/25/2025 |
11 | Class Action Filed Against Capricor Therapeutics, Inc. - September 15, 2025 Deadline to Join Contact Levi Korsinsky | 07/28/2025 |
About Capricor Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Capricor or other stocks. Alpha measures the amount that position in Capricor Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 0.1 | 0.0835 | 0.0412 | 0.0391 | Revenue Per Share | 0.1 | 0.94 | 0.63 | 0.6 |
Capricor Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Capricor Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Capricor Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Capricor Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Capricor Therapeutics. Please utilize our Beneish M Score to check the likelihood of Capricor Therapeutics' management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Capricor Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.